Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Erik Delsing Malmberg, Sofie Johansson Alm, Malin Nicklasson, Vladimir Lazarevic, Sara Ståhlman, Tore Samuelsson, Stig Lenhoff, Julia Asp, Mats Ehinger, Lars Palmqvist, Mats Brune & Linda Fogelstrand. (2019) Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML. Leukemia & Lymphoma 60:2, pages 409-417.
Read now
Read now
Rolf Wouters, David Cucchi, Gertjan JL Kaspers, Gerrit Jan Schuurhuis & Jacqueline Cloos. (2014) Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Review of Hematology 7:6, pages 791-805.
Read now
Read now
Articles from other publishers (21)
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel & Nicholas J. Short. (2021) Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Fateme Karimi Dermani, Saeideh Gholamzadeh Khoei, Saeid Afshar & Razieh Amini. (2021) The potential role of nucleophosmin (NPM1) in the development of cancer. Journal of Cellular Physiology 236:11, pages 7832-7852.
Crossref
Crossref
Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp & Peter J. M. Valk. (2021) Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia. Cancers 13:21, pages 5431.
Crossref
Crossref
Petra Kövy, Zoltán Őrfi, András Bors, András Kozma, László Gopcsa, János Dolgos, Nóra Lovas, József Harasztdombi, Viktor Lakatos, Ágnes Király, Gábor Mikala, István Vályi-Nagy, Péter Reményi & Hajnalka Andrikovics. (2021) Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLOS ONE 16:6, pages e0253386.
Crossref
Crossref
Sanam Loghavi, Courtney D. DiNardo, Ken Furudate, Koichi Takahashi, Tomoyuki Tanaka, Nicholas J. Short, Tapan Kadia, Marina Konopleva, Rashmi Kanagal‐Shamanna, Noushin R. Farnoud, Sherry Pierce, Joseph D. Khoury, Jeffrey L. Jorgensen, Keyur P. Patel, Naval Daver, Musa Yilmaz, L. Jeffrey Medeiros, Hagop Kantarjian, Farhad Ravandi & Sa A. Wang. (2021)
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with
NPM1
‐mutated acute myeloid leukaemia
. British Journal of Haematology 192:6, pages 1054-1063.
Crossref
Crossref
Claudia Sargas, Rosa Ayala, María Carmen Chillón, María J. Larráyoz, Estrella Carrillo-Cruz, Cristina Bilbao, Manuel Yébenes-Ramírez, Marta Llop, Inmaculada Rapado, Ramón García-Sanz, Iria Vázquez, Elena Soria, Yanira Florido-Ortega, Kamila Janusz, Carmen Botella, Josefina Serrano, David Martínez-Cuadrón, Juan Bergua, Mari Luz Amigo, Pilar Martínez-Sánchez, Mar Tormo, Teresa Bernal, Pilar Herrera-Puente, Raimundo García, Lorenzo Algarra, María J. Sayas, Lisette Costilla-Barriga, Esther Pérez-Santolalla, Inmaculada Marchante, Esperanza Lavilla-Rubira, Víctor Noriega, Juan M. Alonso-Domínguez, Miguel Á. Sanz, Joaquín Sánchez-Garcia, María T. Gómez-Casares, José A. Pérez-Simón, María J. Calasanz, Marcos González-Díaz, Joaquín Martínez-López, Eva Barragán & Pau Montesinos. (2020) Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica 106:12, pages 3079-3089.
Crossref
Crossref
Alex Bataller, Guadalupe Oñate, Marina Diaz‐Beyá, Francesca Guijarro, Ana Garrido, Susana Vives, Mar Tormo, Montserrat Arnan, Olga Salamero, Antònia Sampol, Rosa Coll, Ferran Vall‐Llovera, Aina Oliver‐Caldés, Mònica López‐Guerra, Marta Pratcorona, Lurdes Zamora, Eva Villamon, Gaël Roué, Adoración Blanco, Josep F. Nomdedeu, Dolors Colomer, Salut Brunet, Jorge Sierra & Jordi Esteve. (2020)
Acute myeloid leukemia with
NPM1
mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease
. British Journal of Haematology 191:1, pages 52-61.
Crossref
Crossref
Jan Philipp Bewersdorf, Rory M. Shallis, Prajwal C. Boddu, Brent Wood, Jerald Radich, Stephanie Halene & Amer M. Zeidan. (2020) The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. Blood Reviews 43, pages 100650.
Crossref
Crossref
Lauren L. Ritterhouse, Megan Parilla, Chao Jie Zhen, Michelle N. Wurst, Rutika Puranik, Candace M. Henderson, Neda Z. Joudeh, Madeline J. Hartley, Rishikesh Haridas, Pankhuri Wanjari, Larissa V. Furtado, Sabah Kadri & Jeremy P. Segal. (2019) Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Molecular Diagnosis & Therapy 23:6, pages 791-802.
Crossref
Crossref
Farhad Ravandi. (2018) Is it time to routinely incorporate MRD into practice?. Best Practice & Research Clinical Haematology 31:4, pages 396-400.
Crossref
Crossref
Wenjing Peng, Yu Zhang, Rui Zhu & Yehia Mechref. (2017) Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis. ELECTROPHORESIS 38:17, pages 2124-2134.
Crossref
Crossref
Gerald B.W. Wertheim & Adam Bagg. (2017) NPM1 for MRD? Droplet Like It's Hot!. The Journal of Molecular Diagnostics 19:4, pages 498-501.
Crossref
Crossref
Naveen Pemmaraju, Hagop Kantarjian, Jeffrey L. Jorgensen, Elias Jabbour, Nitin Jain, Deborah Thomas, Susan O'Brien, Xuemei Wang, Xuelin Huang, Sa A. Wang, Marina Konopleva, Sergej Konoplev, Tapan Kadia, Rebecca Garris, Sherry Pierce, Guillermo Garcia‐Manero, Jorge Cortes & Farhad Ravandi. (2017)
S
ignificance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
. American Journal of Hematology 92:3, pages 279-285.
Crossref
Crossref
Joseph K. Box, Nicolas Paquet, Mark N. Adams, Didier Boucher, Emma Bolderson, Kenneth J. O’Byrne & Derek J. Richard. (2016) Nucleophosmin: from structure and function to disease development. BMC Molecular Biology 17:1.
Crossref
Crossref
Louise Pettersson, Per Levéen, Olof Axler, Dana Dvorakova, Gunnar Juliusson & Mats Ehinger. (2016)
Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in
Nucleophosmin 1
type a mutated acute myeloid leukemia
. Genes, Chromosomes and Cancer 55:10, pages 750-766.
Crossref
Crossref
Betül Oran, Jorge Cortes, Amer Beitinjaneh, Hsiang-Chun Chen, Marcos de Lima, Keyur Patel, Farhad Ravandi, Xuemei Wang, Mark Brandt, Borje S. Andersson, Stefan Ciurea, Fabio P. Santos, Leandro de Padua Silva, Elizabeth J. Shpall, Richard E. Champlin, Hagop Kantarjian & Gautam Borthakur. (2016) Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation 22:7, pages 1218-1226.
Crossref
Crossref
Bian-Hong Wang, Yong-Hui Li & Li Yu. (2015) Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia. Chinese Medical Journal 128:17, pages 2395-2403.
Crossref
Crossref
Peter Hokland, Hans B. Ommen, Matthew P. Mulé & Christopher S. Hourigan. (2015) Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Seminars in Hematology 52:3, pages 184-192.
Crossref
Crossref
Herschel Mukherjee, Kok-Ping Chan, Vibeke Andresen, Mariah L. Hanley, Bjørn Tore Gjertsen & Andrew G. Myers. (2015) Interactions of the Natural Product (+)-Avrainvillamide with Nucleophosmin and Exportin-1 Mediate the Cellular Localization of Nucleophosmin and its AML-Associated Mutants. ACS Chemical Biology 10:3, pages 855-863.
Crossref
Crossref
Yishai Ofran & Jacob M. Rowe. (2015) Introducing minimal residual disease in acute myeloid leukemia. Current Opinion in Hematology 22:2, pages 139-145.
Crossref
Crossref
John S. Welch. (2014) Mutation Position Within Evolutionary Subclonal Architecture in AML. Seminars in Hematology 51:4, pages 273-281.
Crossref
Crossref